Prorenin and Renin-Induced Extracellular Signal–Regulated Kinase 1/2 Activation in Monocytes Is Not Blocked by Aliskiren or the Handle-Region Peptide

The recently cloned (pro)renin receptor [(P)RR] mediates renin-stimulated cellular effects by activating mitogen-activated protein kinases and promotes nonproteolytic prorenin activation. In vivo, (P)RR is said to be blocked with a peptide consisting of 10 amino acids from the prorenin prosegment called the “handle-region” peptide (HRP). We tested whether human prorenin and renin induce extracellular signal–regulated kinase (ERK) 1/2 activation and whether the direct renin inhibitor aliskiren or the HRP inhibits the receptor. We detected the (P)RR mRNA and protein in isolated human monocytes and in U937 monocytes. In U937 cells, we found that both human renin and prorenin induced a long-lasting ERK 1/2 phosphorylation despite angiotensin II type 1 and 2 receptor blockade. In contrast to angiotensin II-ERK signaling, renin and prorenin signaling did not involve the epidermal growth factor receptor. A mitogen-activated protein kinase kinase 1/2 inhibitor inhibited both renin and prorenin-induced ERK 1/2 phosphorylation. Neither aliskiren nor HRP inhibited binding of 125I-renin or 125I-prorenin to (P)RR. Aliskiren did not inhibit renin and prorenin-induced ERK 1/2 phosphorylation and kinase activity. Fluorescence-activated cell sorter analysis showed that, although fluorescein isothiocyanate–labeled HRP bound to U937 cells, HRP did not inhibit renin or prorenin-induced ERK 1/2 activation. In conclusion, prorenin and renin-induced ERK 1/2 activation are independent of angiotensin II. The signal transduction is different from that evoked by angiotensin II. Aliskiren has no (P)RR blocking effect and did not inhibit ERK 1/2 phosphorylation or kinase activity. Finally, we found no evidence that HRP affects renin or prorenin binding and signaling.

[1]  R. Schmieder,et al.  (Pro)Renin Receptor Peptide Inhibitor “Handle-Region” Peptide Does Not Affect Hypertensive Nephrosclerosis in Goldblatt Rats , 2008, Hypertension.

[2]  D. Müller,et al.  Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor , 2007, Journal of hypertension.

[3]  W. Border,et al.  Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. , 2007, Kidney international.

[4]  R. Dechend,et al.  Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes , 2007, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[5]  P. Pandolfi,et al.  A Novel Signal Transduction Cascade Involving Direct Physical Interaction of the Renin/Prorenin Receptor With the Transcription Factor Promyelocytic Zinc Finger Protein , 2006, Circulation research.

[6]  J. D. den Dunnen,et al.  Prorenin Induces Intracellular Signaling in Cardiomyocytes Independently of Angiotensin II , 2006, Hypertension.

[7]  M. Bader,et al.  Prorenin and its ancient receptor. , 2006, Hypertension.

[8]  A. Nishiyama,et al.  Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. , 2006, Journal of the American Society of Nephrology : JASN.

[9]  E. Park,et al.  Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. , 2006, International journal of molecular medicine.

[10]  A. Nishiyama,et al.  Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  A. Nishiyama,et al.  Nonproteolytic Activation of Prorenin Contributes to Development of Cardiac Fibrosis in Genetic Hypertension , 2006, Hypertension.

[12]  M. Wellner,et al.  Complement Activation in Angiotensin II–Induced Organ Damage , 2005, Circulation research.

[13]  M. Wellner,et al.  Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats , 2005, Hypertension.

[14]  R. Stevenson,et al.  A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor. , 2005, Human molecular genetics.

[15]  R. Schmieder,et al.  Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients , 2005, Circulation.

[16]  A. Nishiyama,et al.  Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. , 2004, The Journal of clinical investigation.

[17]  R. Roberts,et al.  A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy , 2003, The EMBO journal.

[18]  A. Stanton,et al.  Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren , 2003, Hypertension.

[19]  A. Ebihara,et al.  Human Prorenin Has “Gate and Handle” Regions for Its Non-proteolytic Activation* , 2003, Journal of Biological Chemistry.

[20]  R. Stevenson,et al.  AGTR2 Mutations in X-Linked Mental Retardation , 2002, Science.

[21]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[22]  J. Saris,et al.  High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. , 2001, American journal of physiology. Heart and circulatory physiology.

[23]  E. Hahn,et al.  Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies , 2000, Regulatory Peptides.

[24]  J. Laragh,et al.  Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. , 2000, American journal of hypertension.

[25]  S. Eguchi,et al.  Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase , 2000, Regulatory Peptides.

[26]  A. Danser,et al.  Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. , 1997, Hypertension.

[27]  J. Berrou,et al.  Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. , 1996, Kidney international.

[28]  R. Gentz,et al.  Recombinant human renin produced in different expression systems: biochemical properties and 3D structure. , 1996, Protein expression and purification.

[29]  D. Wilson,et al.  Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. , 1990, The New England journal of medicine.

[30]  D. Wilson,et al.  Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. , 1985, The New England journal of medicine.

[31]  W. Hsueh,et al.  A comparison of cold and acid activation of big renin and of inactive renin in normal plasma. , 1978, The Journal of clinical endocrinology and metabolism.

[32]  F. Luft,et al.  An extrarenal source of "renin-like" activity in anephric man. , 1977 .

[33]  J. Laragh,et al.  Plasma prorenin: cryoactivation and relationship to renin substrate in normal subjects. , 1976, The American journal of medicine.

[34]  Ling Yu,et al.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. , 2006, Kidney international.

[35]  J. Laragh,et al.  Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. , 1997, American journal of hypertension.